NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN). Such investors are advised to ...
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the ...
UroGen Pharma completes patient enrollment in Phase 3 UTOPIA trial for UGN-103, a treatment for non-muscle invasive bladder cancer. UroGen Pharma Ltd. has announced the completion of patient ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...
ZUSDURI shows promising long-term efficacy in treating low-grade intermediate-risk bladder cancer, maintaining event-free survival in patients. UroGen Pharma Ltd. announced findings published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results